Search





Search





Markets
/
Stocks
/
kmda
/

Kamada Ltd

KMDA

Add to Watchlist

7.010USD

+0.020+0.29%

Market hours （ET）Quotes delayed by 15 min

404.38MMarket Cap

20.01P/E TTM

Kamada Ltd

7.010

+0.020+0.29%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+0.29%

5 Days

-1.13%

1 Month

-3.44%

6 Months

-20.97%

Year to Date

-0.71%

1 Year

-9.20%

Key Figures

6.910Open

6.998High

11.99KVolume

20.01P/E TTM

11.31P/E Dynamic

0.188Dividend TTM

0.02%Turnover Ratio

6.990Prev. Close

6.890Low

61.03KTurnover

27.96P/E Static

1.56P/B

2.67%Div Yield TTM

5.37%ROA

9.35052wk High

0.40Volume Ratio

14.46MNet Profit

57.69MShares

0.3504EPS TTM

0.87Beta

7.97%ROE

6.50052wk Low

1.55%Amplitude

42.25%Gross Margin

404.38MMarket Cap

-2.61Reward/Risk

1.42%Risk Rate

TradingKey Stock Score of Kamada Ltd

Currency: USD Updated: 2026-07-27

Key Insights

Kamada Ltd's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 80 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kamada Ltd's Score

Industry at a Glance

Industry Ranking

80 / 155

Overall Ranking

178 / 4282

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Kamada Ltd Highlights

StrengthsRisks

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.62% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 180.46M.

Undervalued

The company’s latest PE is 19.95, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 28.17M shares, decreasing 7.11% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 3.03K shares of this stock.